Research Article

Sappanone A Alleviated IL-1β-Induced Inflammation in OA Chondrocytes through Modulating the NF-κB and Nrf2/HO-1 Pathways

Zhi Zhang, Nan-Zhi Zhang, Meng Li, Dang-Feng Zhang, Xing Ma, Shuang-Li Zhou, and Yu-Sheng Qiu

Department of Orthopaedics, The First Affiliated Hospital, College of Medicine, Xi’an Jiaotong University, Xi’an, 710061 Shaanxi, China

Correspondence should be addressed to Yu-Sheng Qiu; qiuiyy@163.com

Received 29 July 2022; Revised 22 August 2022; Accepted 23 August 2022; Published 16 September 2022

Academic Editor: Xiaotong Yang

Copyright © 2022 Zhi Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study was to examine the anti-inflammatory effect of sappanone A on interleukin- (IL-) 1β-stimulated osteoarthritis (OA) chondrocytes.

Methods. Chondrocytes were pretreated with sappanone A for 2 h before subsequent IL-1β stimulation. The mRNA expression levels of iNOS, COX-2, aggrecan, and collagen-II were measured with qRT-PCR. The levels of TNF-α, IL-6, IL-8, MMP-3, and MMP-13 were determined by ELISA. The protein levels of iNOS, COX-2, ADAMTS-4, ADAMTS-5, aggrecan, collagen-II, p-p65, p65, IκBα, Nrf2, and HO-1 were assessed by Western blot.

Results. Sappanone A inhibited the IL-1β-stimulated production of NO, PGE2, iNOS, COX-2, TNF-α, IL-6, and IL-8 in OA chondrocytes. In addition, sappanone A suppressed the expression of MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5 in IL-1β-stimulated OA chondrocytes. The degradation of ECM components was reversed by sappanone A. Sappanone A prevented NF-κB activation while enhanced Nrf2/HO-1 activation in IL-1β-treated chondrocytes.

Conclusion. Sappanone A may be a potent therapeutic agent for OA.

1. Introduction

Osteoarthritis (OA) is a common progressive musculoskeletal disorder that mainly affects weight-bearing joints such as the knee and hip. The lesions include damage and loss of articular cartilage, reconstruction of subarticular bone, formation of bony redundancy, relaxation of the peripheral firmness band, and reduced muscle function [1]. The main symptoms of OA include pain, stiffness, and limited mobility of the joint. Pain in OA is usually classified as either persistent pain or intermittent severe pain that progresses over time. Osteoarthritis is currently one of the major disabling factors in the elderly and seriously affects the quality of life of patients [2]. According to statistics, there are approximately 300 million cases of osteoarthritis worldwide, and the prevalence continues to increase. As one of the most obvious risk factors for osteoarthritis, increasing age leads to a combination of individual exposure to risk factors and age-related biological changes in joint structure, resulting in an increased incidence of osteoarthritis. In addition to age, women, obesity, genetics, nutritional status, and history of trauma are also strong risk factors for osteoarthritis. Despite the more established risk factors associated with the risk of developing OA, little is known about the risk factors associated with the progression of OA, and the etiology of osteoarthritis is still unclear. Common treatment protocols include guidance for weight loss in overweight patients, non-steroidal anti-inflammatory drugs for analgesia, and surgical treatment such as joint replacement [3].

Previously, OA was considered a chronic overload and biomechanical impairment of the joint that impairs articular
cartilage, resulting in stiffness, swelling, and loss of mobility. However, osteoarthritis was found to be a complex pathological process caused by inflammation and abnormal metabolism. During the course of osteoarthritis, the molecular composition of the articular cartilage matrix is altered, and the structural integrity of the tissue is disrupted. The lesion affects the deeper cartilage levels from the cartilage surface as the calcified cartilage area expands. As cartilage is repaired, hypertrophic chondrocytes exhibit a higher degree of activity. Throughout the pathological process, chondrocytes produce large amounts of matrix degradation products and proinflammatory mediators that act on the synovial membrane to stimulate proliferation and inflammatory response. The proliferating synovial cells also release proinflammatory factors that exacerbate the response, while the subchondral bone shows an increased bone turnover rate and blood vessels cross the tidal line from the subchondral bone into the cartilage layer. Increased levels of inflammatory cytokines (mainly IL-1β) are found in synoviocytes and chondrocytes of OA patients [4]. It is known that IL-1β is one critical cytokine in OA progression [5], because it inhibits the production of extracellular matrix (ECM) components and induces the release of major extracellular proteolytic enzymes, such as MMPs and ADAMTSs, thereby promoting the cartilage degeneration [6].

Sappan Lignum is the dried material of Caesalpinia sappan L., family Leguminosae, with the efficacy of activating blood circulation and relieving swelling and pain. Modern pharmacological studies have shown that Sappan Lignum has anti-inflammatory, antibacterial, antitumor, antioxidant, hypoglycemic, and immunosuppressive activities. Sappanone A, one of the active ingredients of Sappan Lignum, can inhibit microglia activation in the brain and has a neuroinflammatory effect. Sappanone A is a homoisoflavonone with strong antioxidant and anti-inflammatory activities [7, 8]. Moreover, sappanone A pretreatment attenuates hypoxia-induced damage in PC-12 cells by inhibiting apoptosis [9]. A recent study showed that sappanone A protects myocardial cells from ischemia-reperfusion-caused injury through its anti-inflammatory effect via modulation of Nrf2 [10]. The study was performed to examine the biological influences of sappanone A on inflammation in OA chondrocytes when culture under IL-1β stimulation.

2. Materials and Methods

2.1. Isolation and Intervention of Human OA Chondrocytes. Articular cartilage specimens from twelve OA patients (6 males, 6 females; aged 24-41 years) were obtained from The First Affiliated Hospital, College of Medicine, Xi’an Jiaotong University (Xi’an, CN). OA chondrocytes of cartilage samples were isolated as noted earlier [11]. The resulting cells were treated with incubation (37°C and 5% CO2) in 10% FBS-contained DMEM.

Human OA chondrocytes were adjusted to 1 × 105 cells per well, followed by 2 h pretreatment with various concentrations of sappanone A. Subsequently, cells were given 24 h treatment (37°C) with IL-1β (10 ng/ml). Sappanone A (purity N98%) was purchased from ChemFaces (Wuhan, CN).

The study protocol and all amendments were approved by the appropriate ethics committee at each center. The study was done in accordance with the protocol, its amendments, and standards of Good Clinical Practice. All participants provided written informed consent before enrolment. Ethics number is MI-US20200203.

2.2. Cell Viability Assay. Chondrocytes (5000 cells/well) were treated with 0, 5, 10, 20, or 40 μM of sappanone A for 24 h. Then, the cells were incubated for 2 h with 10 μl of CCK-8 solution, and the absorbance (450 nm) was detected.

2.3. qRT-PCR. Total RNA of chondrocytes obtained by TRIzol reagent (Invitrogen) was used for cDNA synthesis. The PCR reaction was carried out on CFX96 Real-Time PCR System (Bio-Rad). The mRNA levels of target genes were calculated using the 2-ΔΔCt means, followed by normalization to GAPDH level.

2.4. Western Blot (WB). Whole-cell lysates of chondrocytes were acquired for the following WB assay to determine the following proteins, including ADAMTS-4, iNOS, ADAMTS-5, COX-2, P-p65, aggrecan, p65, Nrf2, collagen-II, iκBα, and HO-1. After separation by SDS-PAGE and transferring to Hybond-P membranes, the proteins were incubated with 1:500 diluted specific primary antibodies against the target protein (Thermo, USA) and 1:3000 diluted secondary antibody (Thermo). The signals were visualized using an enhanced chemiluminescence system (Thermo).

2.5. NO Assay. The Griess reaction approach was used to assess the NO concentration in culture medium using a commercial kit (Beyotime, CN). Samples were mixed with moderate Griess reagent, followed by a 10 min incubation without light. The absorbance (550 nm) was determined.

2.6. ELISA. After treatment, culture supernatants of chondrocytes were acquired for the determination of IL-8, TNF-α, PGE2, IL-6, MMP-3, and MMP-13 concentrations using ELISA kits (R&D, USA).

2.7. Data Analyses. The normality of the sample was determined with the Shapiro–Wilk test. Descriptive statistical data were evaluated with the exploratory analyses of the
Figure 2: Sappanone A decreased IL-1β-induced production of NO and PGE2 in chondrocytes. (a) Griess method for NO concentration analysis. (b) ELISA for PGE2 concentration analysis. *P < 0.05 compared to control group and *P < 0.05 compared to IL-1β treatment group.

Figure 3: Sappanone A suppressed IL-1β-induced expression of iNOS and COX-2 in chondrocytes. (a, b) qRT-PCR analysis for the iNOS and COX-2 mRNA expression. (c, d) WBting analysis for the iNOS and COX-2 protein expression. *P < 0.05 compared to control group and *P < 0.05 compared to IL-1β treatment group.
Tukey test. Quantitative mean data (PES/WES, ISQ, and B.L.) were assessed with the nonparametric Wilcoxon-Mann-Whitney U-test to analyze the inferential statistical. All data are presented by the mean ± SD. Significances among multiple groups were evaluated via the one-way ANOVA analysis of variance. $P < 0.05$ indicates a significant difference.

3. Results

3.1. Impact of Sappanone A on Cell Viability. The concentration of 40 $\mu$M sappanone A produced a significant inhibitory effect on cell viability. Concentrations of 5, 10, and 20 $\mu$M showed no significant change in cell viability. In the following experiments, the concentrations of 5, 10, and 20 $\mu$M were used. (Figure 1).

3.2. Sappanone A Decreased NO and PGE2 Production. NO and PGE2 levels were significantly upregulated by 10 ng/ml IL-1$\beta$ incubation. However, sappanone A significantly reduced the production of NO and PGE2 in IL-1$\beta$ (10 ng/ml)-treated chondrocytes (Figure 2).

3.3. Sappanone A Repressed iNOS and COX-2 Expression. IL-1$\beta$ stimulation led to the upregulated mRNA expression of COX-2 and iNOS. However, sappanone A decreased the mRNA expression of COX-2 and iNOS. Similarly, the protein expression of COX-2 and iNOS was increased with the stimulation by 10 ng/ml IL-1$\beta$; these effects were reversed by sappanone A pretreatment (Figure 3).

3.4. Sappanone A Inhibited Secretion of TNF-α, IL-6, and IL-8. The production of TNF-α, IL-8, and IL-6 was increased significantly in chondrocyte culture supernatants after intervention by 10 ng/ml of IL-1$\beta$, whereas sappanone A alleviated IL-1$\beta$ caused increase in the production of TNF-α, IL-8, and IL-6 in a dose-dependent manner (Figure 4).

3.5. Sappanone A Attenuated the Expression of ADAMTSs and MMPs. Chondrocytes displayed significant upregulation in MMP-13 and MMP-3 production after intervention by 10 ng/ml IL-1$\beta$. However, sappanone A suppressed the MMP-3 and MMP-13 expression. IL-1$\beta$ notably upregulated the protein levels of ADAMTS-5 and ADAMTS-4. Sappanone A remarkably inhibited the increase in protein levels (Figure 5).

3.6. Sappanone A Increased the Expression of Collagen-II and Aggrecan. The mRNA and protein levels of collagen-II and aggrecan were decreased significantly via IL-1$\beta$ stimulation, while sappanone A markedly upregulated the levels of collagen-II and aggrecan in IL-1$\beta$-stimulated chondrocytes (Figure 6).

3.7. Sappanone A Suppressed NF-κB Activation. IL-1$\beta$ notably increased the p-p65 level while decreased the IκBα level. However, sappanone A presented a strong inhibition on IL-1$\beta$-induced changes in p-p65 and IκBα expression levels. The results suggest that sappanone A inhibited IL-1$\beta$-treated NF-κB signaling in chondrocytes (Figure 7).
3.8. Sappanone A Activated Nrf2/HO-1 Signaling. Sappanone A pretreatment promoted nuclear Nrf2 and HO-1 levels in chondrocytes in contrast to 10 ng/ml IL-1β treatment group (Figure 8). Thus, these data suggest that sappanone A took the anti-inflammatory effect through inducing the activation of Nrf2/HO-1.

4. Discussion

OA is a disease of the locomotor system caused by the degradation of the ECM, chondrocyte death, and bone redundancy, characterized by progressive damage to intra-articular cartilage, synovium, ligaments, and periarticular tissues. Current OA treatments are insufficient to arrest the progressive development of OA, and joint replacement is the only available alternative when progressing to advanced stages. Effective interventions for OA are instrumental in improving the quality of life of patients. OA is considered a mismatch disease caused by the body’s inability to adapt to a new and rapidly changing environment and is a degeneration of joint tissue induced by a mismatch between genetics and the environment.

In addition to age-related effects, OA is also associated with a variety of factors such as exercise, obesity, metabolism, and diet, and the mechanisms of action and interrelationships of these relevant factors are poorly understood. The incidence of OA increases with age, and excessive mechanical stress loading of the joints due to excessive exercise and obesity and overweight may also contribute to the onset of OA. However, the association between aging and mechanical stress stimulation, two biological factors that persist in individuals, in the development of OA remains elusive. Inflammatory response with increased releasing of inflammatory cytokines participates in OA development [12, 13]. As a significant proinflammatory cytokine, IL-1β is involved in many inflammation-related diseases including OA. IL-1β action induces the production of different proinflammatory mediators from joint synovium and cartilage [14, 15]. In addition, IL-1β stimulation promotes the secretion of other proinflammatory cytokines, which may induce aggravated secondary insults [16]. The results of the present study found that sappanone A suppressed the production of TNF-α, PGE2, NO, IL-6, and IL-8 and downregulated iNOS and COX-2 expression. A previous study reported that...
sappanone A inhibited these inflammatory molecules in RAW264.7 cells treated by LPS [17], which was consistent with the present study.

OA is classified as “paralysis” in traditional Chinese medicine (TCM) and is caused by a deficiency of the liver and kidneys; cold and dampness invade the ligaments and remain in the joints, blocking the qi flow, resulting in dysregulation of the patient’s qi flow, nondistribution of yang qi, numbness of the skin, and joint pain. Sappan Lignum has the effects of relaxing tendons, activating blood circulation, dispersing knots, sedating, dispelling blood stasis, and relieving pain. It is mainly used for fracture and tendon injury, bruises, stagnant swelling and pain, carbuncle and sores, heart and abdominal pain, blood stagnation and menorrhagia, postpartum stasis and abdominal pain, and dysmenorrhea. It also exhibits antitumor, antioxidant, anticomplement, anti-inflammatory, antibacterial, hypoglycemic, and immunosuppressive effects.

The release of ECM proteolytic enzymes is found to be increased under IL-1β stimulation [18]. MMPs, an important proteolytic system, are responsible for the degradation of ECM [19]. To the best of our knowledge, the inhibition of MMP production may prevent the cartilage degradation [20, 21]. ADAMTSs, expressed in mature articular cartilage, are also important proteolytic enzymes in OA [22]. Thus, medicines targeting MMPs and ADAMTSs may be viable OA therapies. Sappanone A significantly reduced the levels of MMPs and ADAMTSs in chondrocytes in our investigation. According to these findings, sappanone A possesses anti-inflammatory properties against OA. Many studies have shown that IL-1β stimulates the synthesis of ECM components by chondrocytes [23, 24]. Here, we found the capacity of sappanone A to prevent the degradation of aggrecan and collagen-II, which are major articular cartilage matrixes.

NF-κB activation is a key process in OA through the regulation of proinflammatory molecules [25]. IκB-α masks the nuclear localization signals of NF-κB proteins by maintaining them in cytoplasm at an inactive state, thereby inhibiting the NF-κB activation [26]. Lee et al. [27] reported that sappanone A inhibited NF-κB activation stimulated by LPS in RAW264.7 cells. Similarly, in the present study, sappanone A markedly suppressed NF-κB activation in chondrocytes under IL-1β stimulation. Nrf2 is a critical transcription factor against oxidative damage [28]. Additionally, Nrf2 signaling...
Figure 7: Sappanone A suppressed IL-1β-induced NF-κB activation in chondrocytes. WBting analysis for the protein levels of p-p65, p65, and Ikbα. *P < 0.05 compared to control group and *P < 0.05 compared to IL-1β treatment group.

Figure 8: Sappanone A activated Nrf2/HO-1 signaling pathway in IL-1β-induced chondrocytes. Western blotting analysis for the protein levels of Nrf2 and HO-1. *P < 0.05 compared to control group and *P < 0.05 compared to IL-1β treatment group.
also regulates the inflammatory response. Dysfunction of Nrf2 increases the risk of inflammatory diseases occurring [29–31]. The present study showed that sappanone A notably upregulated the protein levels of HO-1 and Nrf2 in chondrocytes.

The study still has some limitations: the study only measured the indices at a single time point and did not consider the timeliness of sappanone A. The study design was flawed in that serum specimens were used for the detection of inflammatory factors, but not joint effusion or synovial tissue.

In conclusion, sappanone A suppressed the IL-1β-induced production of proinflammatory mediators and cytokines in OA chondrocytes. Sappanone A also suppressed the expression of ECM proteolytic enzymes and the degradation of ECM components. Mechanistic studies showed that sappanone A inhibited NF-κB activation and induced Nrf2/HO-1 signaling.

Data Availability
All data generated or analyzed during this study are included in this published article.

Conflicts of Interest
All authors declared that they have no financial conflict of interest.

References
[1] J. W. Bijlsma, F. Berenbaum, and F. P. Lafeber, "Osteoarthritis: an update with relevance for clinical practice," Lancet, vol. 377, no. 9783, pp. 2115–2126, 2011.
[2] A. E. Weber, I. K. Bolia, and N. A. Trasolini, "Biological strategies for osteoarthritis: from early diagnosis to treatment," International Orthopaedics, vol. 1-10, 2021.
[3] S. S. Shah and M. Kai, "Current applications of growth factors for knee cartilage repair and osteoarthritis treatment," Current Reviews in Musculoskeletal Medicine, vol. 13, no. 6, pp. 641–650, 2020.
[4] W. Srisuthiyananont, D. Pruskakorn, P. Kongtawelert, and P. Pothacharoen, "Effects of sesamin on chondroitin sulfate proteoglycan synthesis induced by interleukin-1beta in human chondrocytes," BMC Complementary and Alternative Medicine, vol. 17, no. 1, p. 286, 2017.
[5] C. J. Malemud, N. Islam, and T. M. Haqqi, "Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies," Cells, Tissues, Organs, vol. 174, no. 1-2, pp. 34–48, 2003.
[6] B. Yang, J. Ni, H. Long, J. Huang, C. Yang, and X. Huang, "IL-1β-induced miR-34a up-regulation inhibits Cyr61 to modulate osteoarthritis chondrocyte proliferation through ADAMTS-4," Journal of Cellular Biochemistry, vol. 119, no. 10, pp. 7959–7970, 2018.
[7] L. Kang, H. Zhao, C. Chen, X. Zhang, M. Xu, and H. Duan, "Sappanone A protects mice against cisplatin-induced kidney injury," International Immunopharmacology, vol. 38, pp. 246–251, 2016.
[8] X. Liu, D. Yu, and T. Wang, "Sappanone A attenuates allergic airway inflammation in ovalbumin-induced asthma," International Archives of Allergy and Immunology, vol. 170, no. 3, pp. 180–186, 2016.
[9] C. Kang, J. Gao, M. Kang, X. Liu, Y. Fu, and L. Wang, "RETRACTED: Sappanone A prevents hypoxia-induced injury in PC-12 cells by down-regulation of miR-15a," International Journal of Biological Macromolecules, vol. 123, pp. 35–41, 2019.
[10] X. Shi, G. Tao, L. Ji, and G. Tian, "Sappanone A protects against myocardial ischemia reperfusion injury by modulation of Nrf2," Drug Design, Development and Therapy, vol. 14, pp. 61–71, 2020.
[11] Y. U. Xiao, L. I. Bing, J. Liu, and M. A. Xinlong, "Carvacrol ameliorates inflammatory response in interleukin 1β-stimulated human chondrocytes," Molecular Medicine Reports, vol. 17, pp. 3987–3992, 2018.
[12] J. Buckland, "Osteoarthritis: complement-mediated inflammation in OA progression," Nature Reviews Rheumatology, vol. 8, no. 1, p. 2, 2012.
[13] R. Terkeltaub, "Emerging paradigm: roles of inflammation in OA," Osteoarthritis and Cartilage, vol. 21, p. S7, 2013.
[14] L. Dai, X. Zhang, X. Hu, C. Zhou, and Y. Ao, "Silencing of microRNA-101 prevents IL-1β-induced extracellular matrix degradation in chondrocytes," Arthritis Research & Therapy, vol. 14, no. 6, p. R268, 2012.
[15] T. T. Chowdhury, L. B. Dan, and D. A. Lee, "Dynamic compression inhibits the synthesis of nitric oxide and PGE2 by IL-1β-stimulated chondrocytes cultured in agarose constructs," Biochemical and Biophysical Research Communications, vol. 285, no. 5, pp. 1168–1174, 2001.
[16] Y. Aida, M. Maeno, N. Suzuki et al., "The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes," Life Sciences, vol. 79, no. 8, pp. 764–771, 2006.
[17] S. Lee, S. Choi, Y. Choo et al., "Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-kappa B," International Immunopharmacology, vol. 28, no. 1, pp. 328–336, 2015.
[18] W. Zheng, Z. Tao, L. Cai et al., "Chrysins attenuates IL-1 beta-induced expression of inflammatory mediators by suppressing NF-κB in human osteoarthritic chondrocytes," Inflammation, vol. 40, no. 4, pp. 1143–1154, 2017.
[19] T. Klein and R. Bischoff, "Physiology and pathophysiology of matrix metalloproteases," Amino Acids, vol. 41, no. 2, pp. 271–290, 2011.
[20] J. A. Mengshol, K. S. Mix, and C. E. Brinckerhoff, "Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull’s-eye or missing the mark?," Arthritis and Rheumatism, vol. 46, no. 1, pp. 13–20, 2002.
[21] S. W. Yin, Y. H. Yun, F. Y. Rui, W. Zhen, and Y. W. Yi, "The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit," Medical Hypotheses, vol. 69, no. 3, pp. 557–559, 2007.
[22] J. Buckland, "Osteoarthritis: positive feedback between ADAMTS-7 and TNF in OA," Nature Reviews Rheumatology, vol. 9, no. 10, p. 566, 2013.
[23] B. Zhu, G. Cui, Q. Zhang, X. Cheng, and S. Tang, "Desumoylation of aggrecan and collagen II facilitates degradation via aggrecanases in IL-1β-mediated osteoarthritis," Journal of Pain Research, vol. 12, pp. 2145–2153, 2019.
[24] N. Hu, X. Gong, S. Yin, Q. Li, and J. Li, "Saxagliptin suppresses degradation of type II collagen and aggrecan in primary
human chondrocytes: a therapeutic implication in osteoarthritis,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 47, no. 1, pp. 3239–3245, 2019.

[25] S. Rigoglou and A. G. Papavassiliou, "The NF-κB signalling pathway in osteoarthritis," The International Journal of Biochemistry & Cell Biology, vol. 45, no. 11, pp. 2580–2584, 2013.

[26] P. P. Tak and G. S. Firestein, "NF-kappaB: a key role in inflammatory diseases," The Journal of Clinical Investigation, vol. 107, no. 1, pp. 7–11, 2001.

[27] S. Lee, S. Choi, Y. Choo et al., “Sappanone A exhibits anti-inflammatory effects via modulation of Nrf2 and NF-κB,” International Immunopharmacology, vol. 28, no. 1, pp. 328–336, 2015.

[28] M. Schaefer and S. Werner, "Nrf2-a regulator of keratinocyte redox signaling," Free Radical Biology & Medicine, vol. 88, no. - Part B, pp. 243–252, 2015.

[29] S. M. U. Ahmed, L. Luo, A. Namani, X. J. Wang, and X. Tang, "Nrf2 signaling pathway: pivotal roles in inflammation," Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1863, no. 2, pp. 585–597, 2017.

[30] C. Jiang, P. Luo, X. Li, P. Liu, Y. Li, and J. Xu, “Nrf2/ARE is a key pathway for curcumin-mediated protection of TMJ chondrocytes from oxidative stress and inflammation,” Cell Stress & Chaperones, vol. 25, no. 3, pp. 395–406, 2020.

[31] W. Li, T. O. Khor, C. Xu et al., “Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis,” Biochemical Pharmacology, vol. 76, no. 11, pp. 1485–1489, 2008.